MRI Guided Focal Laser Ablation of Prostate Cancer

Prostate Cancer Clinical Trial

— MRgFLA  

Official title:

MRI Guided Focal Laser Ablation of Prostate Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03650595
• Other study ID #: 15-9002
• Status: Recruiting
• Phase: N/A
• Start date: March 29, 2018
• Est. completion date: June 30, 2022

Study information

• Verified date: August 2020
• Source: University Health Network, Toronto
• Contact: Sangeet Ghai, MD
• Phone: 416-340-4800
• Email: sangeet.ghai[@]uhn.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This clinical research study is designed to determine the ability of in bore MRI guided Focal Laser Ablation (MRgFLA) in patients with early stage carcinoma of prostate. The results will be evaluated by repeated MRI and prostate biopsy. Previous prospective development study demonstrated that FLA may be a viable option for men with low-intermediate risk prostate cancer. The vast majority of patients undergoing this treatment experienced minimal side effects with no peri-operative complications. Over 80% of patients treated with MRgFLA remain on AS and were able to avoid radical therapy at mean follow up duration of 3 years.

Description:

Study Objectives are to evaluate the proportion of patients with low-intermediate risk prostate cancer undergoing focal laser ablation (MRgFLA) prostate treatment who will be free of clinically significant Prostate Cancer (PCa), when using a > 5mm margins around the MR visible tumor in defining the ablation contour. The rationale of the study is to show that MRgFLA is a safe procedure that can significantly postpone or eliminate the need for patients with Low-Intermediate Risk prostate cancer to undergo a definitive treatment (i.e., Radical Prostatectomy or Radiation therapy) for their disease. Study population: patients with Low-Intermediate Risk Prostate Cancer who are willing to take part in the study and meet study eligibility criteria. Primary Study Objective is to show that MRgFLA can significantly reduce the need for definitive treatment (e.g., Radical Prostatectomy, or Radiation therapy) and is a safe procedure for patients with Low-Intermediate Risk Prostate Cancer defined in the current protocol as 1) Gleason score 6 and 7 (=3+4 or 4+3; No Grade 5 pattern), and 2) T1-T2, N0, M0.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: June 30, 2022
• Est. primary completion date: June 30, 2021
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 40 Years to 80 Years

Eligibility

Inclusion Criteria:

• Men 40-80 years of age;

• Histologically-proven low-intermediate risk prostate carcinoma; (Gleason score = 7, primary grade = 4)

• Prostate cancer clinical stage T1c and T2

• MR site suspicious for cancer or cancer mapped to one lobe of the prostate using the 3D hybrid Trans-rectal ultrasound (TRUS) device

• Size of MR visible tumor <20mm

• Suspicious site on Prostate MRI must coincide with sector positive for cancer on biopsy.

• Prostate specific antigen (PSA) level less than 15 ng/mL

• IPSS, International Consultation on Incontinence Questionnaire-Urinary Incontinence-Short Form (ICIQ-UI SF), IIEF complete prior to procedure

• Life expectancy of greater than 10 years, based on co-morbidity not related to prostate cancer.

Exclusion Criteria:

• Medically unfit for focal therapy of the prostate

• Patients who are unwilling or unable to give informed consent;

• Patients who have received androgen suppression therapy

• Patients who have received or are receiving chemotherapy for prostate carcinoma;

• Patients previously treated with surgery to the prostate (traditional, endoscopic or minimally invasive including High-Intensity Focused Ultrasound (HIFU), Transurethral Needle Ablation (TUNA), Radiofrequency Interstitial Tumor Ablation (RITA), microwave, cryotherapy or any curative treatment

• Patients who have undergone radiation therapy for prostate cancer or to the pelvis

• Any condition, or history of illness or surgery that, in the opinion of the Investigator, might confound the results of the study or pose additional risks to the patient (e.g. significant cardiovascular conditions or allergies);

• Patients with a history of non compliance with medical therapy and/or medical recommendations;

• Patients who are unwilling or unable to complete the patient self-assessment questionnaires;

• Chronic or acute prostatitis, neurogenic bladder, urinary tract infection, sphincter abnormalities, or any other symptom that prevents normal micturition.

• Patients who have participated in a clinical study and/or received treatment with an investigational treatment and/or product within the past 90 days;

• Patients with contraindication to MRI (i.e. pacemaker, hip prosthesis, severe claustrophobia, brain aneurysm clip, allergy to MRI contrast agent)

• Any condition, or history of illness that, in the opinion of the investigator will confound or increase the patient risk during the study

Related Conditions & MeSH terms

• Low and Intermediate Risk Prostate Cancer
• Prostate Cancer
• Prostatic Neoplasms

Intervention

Device:
• The TRANBERGCLS|Thermal Therapy
MRI Guided Focal Laser Ablation of Prostate Cancer by The Diode Laser System - The TRANBERGCLS|Thermal Therapy

Locations

Country	Name	City	State
Canada	Sangeet Ghai, MD	Toronto	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
University Health Network, Toronto	Clinical Laserthermia Systems AB

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The proportion of study patients clinically free of clinically significant PCa (i.e. requires definitive treatment)	Clinically significant PCa will be defined as recurrent/residual Gleason 3+4 or higher, and/or high volume Gleason 6 disease found at 6 month biopsy.	6 months after treatment completion
Primary	The proportion of study patients clinically free of clinically significant PCa (i.e. requires definitive treatment)	Clinically significant PCa will be defined as recurrent/residual Gleason 3+4 or higher, and/or high volume Gleason 6 disease found at 24 month biopsy.	24 months after treatment completion
Secondary	Treatment effect on patients' Quality of Life (QoL), the following validated self-reported urogenital functioning assessment instruments will be used before and following treatment at pre-specified interval	Validate Patient-Reported Questionnaire (International Prostate Symptom Score, scale from 0-7 mild, 8-19 moderate, 20-35 severe symptoms, higher values being worse, averages at different time points will be noted to assess improvement, decline or baseline) will be completed by participants throughout the study to assess Health Related Quality of Life.	Baseline before treatment, 30 days, 6 months, 12 months and at 24 months following treatment
Secondary	Treatment effect on patients' Quality of Life (QoL), the following validated self-reported urogenital functioning assessment instruments will be used before and following treatment at pre-specified interval	Validate Patient-Reported Questionnaire (International Index of Erectile Function-15, higher scores are better, averages at each specified interval will be taken once all subjects reach the interval and study completion) will be completed by participants throughout the study to assess Health Related Quality of Life.	Baseline before treatment, 30 days, 6 months, 12 months and at 24 months following treatment